Diagnostic utility of anti-Saccharomyces cerevisiae antibody (ASCA) and Interferon-? assay in the differential diagnosis of Crohn's disease and intestinal tuberculosis

Clinica Chimica Acta

Volumn 412, Issue 17-18, 2011, Pages 1527-1532

  Kim, You Sun ^a   Kim, Young Ho ^b   Kim, Won Ho ^c   Kim, Joo Sung ^d   Park, Young Sook ^e   Yang, Suk Kyun ^f   Ye, Byong Duk ^f   Jang, Byung Ik ^g   Jung, Sung Ae ^h   Jeen, Yoon Tae ⁱ   Cheon, Jae Hee ^c   Choi, Yong Sung ^j   Choi, Jai Hyun ⁱ   Kim, Beom Jin ^k   Choi, Chang Hwan ^k   Han, Dong Soo ^l  

^a Inje University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Eulji University   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Yeungnam University College of Medicine   (South Korea)

^h Ewha Womans University School of Medicine   (South Korea)

ⁱ Korea University College of Medicine   (South Korea)

^j Daehang Hospital   (South Korea)

^k Chung Ang University College of Medicine   (South Korea)

^l Hanyang University   (South Korea)

more..

Author keywords

Anti Saccharomyces cerevisiae antibody; Crohn's disease; INF gamma assay; Intestinal tuberculosis

Indexed keywords

FUNGUS ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; INSTRUMENT VALIDATION; INTERMETHOD COMPARISON; INTESTINE TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIBODIES, FUNGAL; CASE-CONTROL STUDIES; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERFERON-GAMMA; INTESTINAL DISEASES; SACCHAROMYCES CEREVISIAE; TUBERCULOSIS;

SACCHAROMYCES CEREVISIAE;

EID: 79959295334     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.04.029     Document Type: Article

References (40)

1. Dye C. Global epidemiology of tuberculosis. Lancet 2006, 367:938-940.
2. Edginton M.E., Wong M.L., Phofa R., Mahlaba D., Hodkinson H.J. Tuberculosis at Chris Hani Baragwanath Hospital: numbers of patients diagnosed and outcomes of referrals to district clinics. Int J Tuberc Lung Dis 2005, 9:398-402.
3. Logan I., Bowlus C.L. The geoepidemiology of autoimmune intestinal diseases. Autoimmun Rev 2010 Mar, 9:A372-A378.
4. Yang S.K., Yun S., Kim J.H., et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis 2008, 14:542-549.
5. Jayanthi V., Robinson R.J., Malathi S., et al. Does Crohn's disease need differentiation from tuberculosis?. J Gastroenterol Hepatol 1996, 11:183-186.
6. Epstein D., Watermeyer G., Kirsch R. Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis. Aliment Pharmacol Ther 2007, 25:1373-1388.
7. Pulimood A.B., Ramakrishna B.S., Kurian G., et al. Endoscopic mucosal biopsies are useful in distinguishing granulomatous colitis due to Crohn's disease from tuberculosis. Gut 1999, 45:537-541.
8. Kirsch R., Pentecost M., Hall Pde M., Epstein D.P., Watermeyer G., Friederich P.W. Role of colonoscopic biopsy in distinguishing between Crohn's disease and intestinal tuberculosis. J Clin Pathol 2006, 59:840-844.
9. Lee Y.J., Yang S.K., Byeon J.S., et al. Analysis of colonoscopic findings in the differential diagnosis between intestinal tuberculosis and Crohn's disease. Endoscopy 2006, 38:592-597.
10. Pulimood A.B., Peter S., Ramakrishna B., et al. Segmental colonoscopic biopsies in the differentiation of ileocolic tuberculosis from Crohn's disease. J Gastroenterol Hepatol 2005, 20:688-696.
11. Yang S.K. Current status and clinical characteristics of inflammatory bowel disease in Korea. Korean J Gastroenterol 2002, 40:1-14.
12. Kim H.D., Kim C.G., Kim J.W., et al. Clinical features and therapeutic responses of perianal lesions in Crohn's disease. Korean J Gastroenterol 2003, 42:128-133.
13. Park J.B., Yang S.K., Myung S.J., et al. Clinical characteristics at diagnosis and course of Korean patients with Crohn's disease. Korean J Gastroenterol 2004, 43:8-17.
14. Main J., McKenzie H., Yeaman G.R., et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988, 297:1105-1106.
15. Sendid B., Colombel J.F., Jacquinot P.M., et al. Specific antibody response to oligomannosidic epitopes in Crohn's disease. Clin Diagn Lab Immunol 1996, 3:219-226.
16. Vasiliauskas E.A., Kam L.Y., Karp L.C., Gaiennie J., Yang H., Targan S.R. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000, 47:487-496.
17. Ruemmele F.M., Targan S.R., Levy G., Dubinsky M., Braun J., Seidman E.G. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998, 115:822-829.
18. Kim B.C., Park S., Han J., Kim J.H., Kim T.I., Kim W.H. Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course. Dig Liver Dis 2007, 39:610-616.
19. Kim B.G., Kim Y.S., Kim J.S., Jung H.C., Song I.S. Diagnostic role of anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. Dis Colon Rectum 2002, 45:1062-1069.
20. Amarapurkar D.N., Patel N.D., Rane P.S. Diagnosis of Crohn's disease in India where tuberculosis is widely prevalent. World J Gastroenterol 2008, 14:741-746.
21. Ghoshal U.C., Ghoshal U., Singh H., Tiwari S. Anti-Saccharomyces cerevisiae antibody is not useful to differentiate between Crohn's disease and intestinal tuberculosis in India. J Postgrad Med 2007, 53:166-170.
22. Makharia G.K., Sachdev V., Gupta R., Lal S., Pandey R.M. Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig Dis Sci 2007, 52:33-39.
23. Caputo D., Alloni R., Garberini A., et al. Experience with two cases of intestinal tuberculosis: utility of the QuantiFERON-TB Gold test for diagnosis. Surg Infect (Larchmt) 2008, 9:407-410.
24. Kim B.J., Choi Y.S., Jang B.I., et al. Prospective evaluation of the clinical utility of Interferon-? assay in the differential diagnosis of intestinal tuberculosis and Crohn's disease. Inflamm Bowel Dis 2011, 17:1308-1313.
25. Yao T., Matsui T., Hiwatashi N. Crohn's disease in Japan: diagnostic criteria and epidemiology. Dis Colon Rectum 2000, 43:S85-S93.
26. Korean TB Surveillance System: http://tbnet.nih.go.kr.
27. Pulimood A.B., Peter S., Rook G.W., Donoghue H.D. In situ PCR for Mycobacterium tuberculosis in endoscopic mucosal biopsy specimens of intestinal tuberculosis and Crohn disease. Am J Clin Pathol 2008, 129:846-851.
28. Vermeire S., et al. Comparative study of ASCA assays in inflammatory bowel disease. Gastroenterology 2001, 120:827-833.
29. Heelan B.T., Allan S., Barnes R.M. Identification of a 200-kDa glycoprotein antigen of Saccharomyces cerevisiae. Immunol Lett 1991, 28:181-185.
30. Mpofu C.M., Campbell B.J., Subramanian S., et al. Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn's disease. Gastroenterology 2007, 133:1487-1498.
31. Harrer M., Reinisch W., Dejaco C., et al. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease?. Eur J Gastroenterol Hepatol 2003, 15:1281-1285.
32. Joossens S., Suenaert P., Noman M., Vermeire S., Rutgeerts P. Saccharomyces boulardii in Crohn's disease: effect on anti-Saccharomyces cerevisiae antibodies and intestinal permeability. Inflamm Bowel Dis 2005, 11:863-864.
33. McKenzie H., Main J., Pennington C.R., Parratt D. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut 1990, 31:536-538.
34. Israeli E., Grotto I., Gilburd B., et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005, 54:1232-1236.
35. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006, 52:171-181.
36. Gardam M.A., Keystone E.C., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-155.
37. Quinton J.F., Sendid B., Reumaux D., et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998, 42:788-791.
38. Peeters M., Joossens S., Vermeire S., Vlietinck R., Bossuyt X., Rutgeerts P. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001, 96:730-734.
39. Halfvarson J., Standaert-Vitse A., Jarnerot G., et al. Anti-Saccharomyces cerevisiae antibodies in twins with inflammatory bowel disease. Gut 2005, 54:1237-1243.
40. Walker L.J., Aldhous M.C., Drummond H.E., et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations. Clin Exp Immunol 2004, 135:490-496.